|Articles|December 15, 2013
Creating Better Medicines through Better Conjugation (PDF)
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Advertisement
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
3
Biopharma’s 2025 Transformation: A Recap of Our Top 10 Articles
4
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
5